Advertisement

Research Article Free access | 10.1172/JCI113783

Human tissue-type plasminogen activator releases fibrinopeptides A and B from fibrinogen.

J I Weitz, M K Cruickshank, B Thong, B Leslie, M N Levine, J Ginsberg, and T Eckhardt

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Find articles by Weitz, J. in: JCI | PubMed | Google Scholar

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Find articles by Cruickshank, M. in: JCI | PubMed | Google Scholar

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Find articles by Thong, B. in: JCI | PubMed | Google Scholar

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Find articles by Leslie, B. in: JCI | PubMed | Google Scholar

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Find articles by Levine, M. in: JCI | PubMed | Google Scholar

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Find articles by Ginsberg, J. in: JCI | PubMed | Google Scholar

Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Find articles by Eckhardt, T. in: JCI | PubMed | Google Scholar

Published November 1, 1988 - More info

Published in Volume 82, Issue 5 on November 1, 1988
J Clin Invest. 1988;82(5):1700–1707. https://doi.org/10.1172/JCI113783.
© 1988 The American Society for Clinical Investigation
Published November 1, 1988 - Version history
View PDF
Abstract

In five patients with venous thromboembolic disease treated with recombinant tissue-type plasminogen activator (rt-PA), there was a marked increase in the mean concentrations of fibrinopeptide A (from 0.6 to 5.9 nM; P less than 0.0001) and desarginine fibrinopeptide B (from 5.6 nM to 24.1 nM; P less than 0.01) 30 min after a bolus of rt-PA (0.6 mg/kg). Thrombin was unlikely to be responsible because the levels of desarginine fibrinopeptide B exceeded those of fibrinopeptide A and the changes occurred despite concomitant heparin therapy. The purpose of this study therefore, was to determine whether rt-PA directly releases the fibrinopeptides from fibrinogen. Incubation of rt-PA with heparinized plasma or purified fibrinogen resulted in time and dose-dependent release of both fibrinopeptide A and B. Contaminating thrombin was not responsible for this activity by the following criteria: the rate of rt-PA mediated fibrinopeptide B release was considerably faster than that of fibrinopeptide A, and fibrinopeptide release was unaffected by heparin, hirudin, or a monospecific antithrombin IgG. Aprotinin also had no effect on fibrinopeptide release, indicating that this activity was not plasmin mediated. Fibrinopeptide release was shown to be due to rt-PA because this activity was completely blocked by a monoclonal antibody against the enzyme. Further, the specificity of rt-PA for the thrombin cleavage sites on fibrinogen was confirmed by the demonstration that rt-PA released fibrinopeptide A or fibrinopeptide B from fibrinopeptide A or B-containing substrates, respectively. These studies thus demonstrate that (a) rt-PA releases fibrinopeptides A and B from fibrinogen thereby indicating that this enzyme is not specific for plasminogen, and (b) plasma fibrinopeptide A and desarginine fibrinopeptide B levels are not specific markers of thrombin action on fibrinogen in patients receiving rt-PA.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Version history
  • Version 1 (November 1, 1988): No description
Advertisement
Advertisement